All In MedTech

Device Trial Radar · NCT06120205

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

SELF-CERV Pivotal Study: Method Comparison of Self-collection Using the Teal Wand Self-Collection Device and HCP (Health Care Provider) Cervical Collection for Detection of High-risk HPV (hrHPV) for Cervical Cancer Screening

Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

870

Planned (sponsor's estimate)

Start

Nov 20, 2023

Primary completion

Apr 5, 2024

Study completion Jun 1, 2027

Sponsor

Lead sponsor
Teal Health, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Nov 7, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
FDA-regulated device
Yes
Who can join
Female only, from 25 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this method comparison study is to compare the detection of hrHPV collected using the Teal Wand Self-Collection device to hrHPV detected from HCP (health care provider) cervical collection using primary HPV testing assays. Participants will be asked to use the Teal Wand to provide a self-collected sample prior to a healthcare provider collected sample to be tested for hrHPV. Secondary measure will include usability and preferences.

Conditions

  • Hpv
  • HPV 16 Infection
  • HPV Infection
  • High Risk HPV

Interventions

  • Teal Wand Self-Collection Device GroupDevice

    Participants will use the Instructions for Use to perform self-collection of vaginal cells and material using the Teal Wand Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A healthcare provider collected sample will be performed by a clinician after self-collection. The patient will serve as their own comparator/control.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy: Detection of hrHPV in self-collect and clinician collect samplesTime frame: Samples tested within 7 days of collection
  2. Safety: SAE rateTime frame: 6-14 days following collections

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Birmingham OBGYN / Alabama Clinical Therapeutics

    Birmingham, Alabama

  • Planned Parenthood Northern California

    San Francisco, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.